The core business is performing well with raised sales guidance and strong launch momentum (WINREVAIR, KEYTRUDA QLEX, LIPFENDRA), but the EPS guidance cut from acquisition charges creates headline noise. Traders should focus on operational trends excluding one-time items and watch for pipeline catalysts (KEYTRUDA label expansions, LIPFENDRA launch trajectory, Terns integration). The stock may trade on ex-charge operational momentum rather than GAAP losses.
Drugs in focus
MRK drug pipeline →GARDASIL
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially marketed since 2014 (GARDASIL 9).
- Next catalyst
- None dated
What to watchWatch for the confirmatory trial readout for the oropharyngeal/head-and-neck cancer indication (no date announced), which could convert the accelerated approval to full approval or, in a negative scenario, narrow the label. Also monitor quarterly Gardasil sales trends for evidence of a China demand recovery or further deterioration, and the progress of Merck's single-dose regimen trials, which could expand the addressable market if successful.
- ▲ WINREVAIR 4/10 Approved Named in filing
- ● BRIDION 3/10 Approved Named in filing
- ● PREVYMIS 2/10 Approved (for CMV prophylaxis in HSCT). Phase 2 completed for lung transplant indication (NCT05041426). Named in filing
- ● Lynparza Fresh report · subscribers
- ● ENFLONSIA 4/10 Approved · PDUFA date Mar 22, 2027
- 15 more · All MRK drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 4 $128.00entry
- T+1 · 3mo ago +0.26%α +0.46% · $128.33
- T+5 · 3mo ago +1.89%α +1.99% · $130.42
- T+20 · 3mo ago +17.08%α +18.32% · $149.86
- T+60 · 20d ago +10.80%α +11.01% · $141.82
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Merck reported Q2 2026 revenue of $16.6B (+5% YoY), beating consensus of $16.37B, and non-GAAP EPS of -$0.13 vs consensus -$0.26 (a 50% beat). The company raised its full-year sales guidance to $66.3B-$67.3B but lowered non-GAAP EPS guidance to $2.66-$2.76 due to $2.31/share charge from the Terns acquisition. Operational strength in oncology (KEYTRUDA QLEX uptake, WINREVAIR +75%) and new product launches (LIPFENDRA approval) was offset by acquisition-related losses and declining legacy franchises (GARDASIL, JANUVIA).
Key Financial Metrics
Key Facts
- Q2 2026 sales $16,607M (+5% YoY; +4% ex-FX)
- Non-GAAP EPS -$0.13 vs consensus -$0.26 (beat by 50%)
- KEYTRUDA/KEYTRUDA QLEX combined sales $8,366M (+5% YoY); KEYTRUDA QLEX contributed $463M
- WINREVAIR sales $588M (+75% YoY)
- Full-year 2026 sales guidance raised to $66.3B-$67.3B from $65.8B-$67.0B
- Full-year non-GAAP EPS guidance lowered to $2.66-$2.76 from $5.04-$5.16 due to $2.31/share Terns acquisition charge
- GAAP loss per share -$0.54; non-GAAP loss per share -$0.13
- Completed acquisition of Terns Pharmaceuticals for $6.8B
- FDA approved LIPFENDRA (enlicitide), first oral PCSK9 inhibitor
- Gross margin (GAAP) 73.5% vs 77.5% a year ago; non-GAAP gross margin 81.1% vs 82.2%
Financial Impact
Revenue beat by $237M (1.45%); EPS beat by $0.13 (50%); sales guidance raised by ~$0.4B at midpoint; EPS guidance lowered by ~$2.39 at midpoint due to acquisition charges
Risk Factors
- KEYTRUDA faces patent cliff (LOE expected late 2028); pipeline replacement risk
- GARDASIL sales declining in China (-19% in Q1, +4% in Q2 but volatile)
- Integration of Terns and Cidara acquisitions may dilute near-term EPS further
- Non-GAAP EPS guidance of $2.66-$2.76 implies H2 2026 EPS of ~$4.07-$4.17 (excluding charges) vs H1 loss; execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-090045 |
| Document: tm2621496d1_ex99-1.htm | 0001104659-26-090045 |
| Document: tm2621496d1_8k.htm | 0001104659-26-090045 |
| Document: 0001104659-26-090045-index-headers.html | 0001104659-26-090045 |
| Document: 0001104659-26-090045-index.html | 0001104659-26-090045 |
| Document: 0001104659-26-090045.txt | 0001104659-26-090045 |
| 8-K Data (Synthetic) | 0001104659-26-090045 |
Track record
34 reports on MRK
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.92% at T+20 after the Aug 6, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $147.76 Now $144.46 −2.23% settles Feb 11
- Nov 9, 20268d ago PTAB Trial Neutral 2/10 Entry $148.05 Now $144.46 −2.42% settles Feb 8
- Nov 3, 202613d ago 3 Neutral 2/10 Entry $144.67 Now $144.46 −0.15% settles Feb 1
- Nov 3, 202613d ago Institutional Cluster Bearish 4/10 Entry $144.67 Now $144.46 +0.15% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $144.67 Now $144.46 −0.15% settles Feb 1
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $146.33 Now $144.46 −1.28% settles Jan 27
- Oct 22, 202625d ago 3/A Neutral 1/10 Entry $145.27 Now $144.46 −0.56% settles Jan 21
- Oct 21, 202627d ago PTAB Trial Neutral 3/10 Entry $147.24 Now $144.46 −1.89% settles Jan 20
- Oct 15, 20264w ago PTAB Trial Bullish 6/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
- Oct 15, 20264w ago PTAB Trial Bullish 5/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers